WVU in the News: WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy
A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab in treating one of the rarest and most aggressive forms of leukemia.
The investigator-initiated Phase II clinical trial, led by Ashkan Emadi, M.D., Ph.D., principal investigator of the study and Alexander Bland Osborn Distinguished Professor of Medical Oncology in the WVU School of Medicine, marks the first-ever use of a subcutaneous formulation delivery for blinatumomab in CD19-positive mixed phenotype acute leukemia (MPAL).
Related Stories
‘Unprecedented’ early results reported in WVU Medicine leukemia trial - Pittsburgh Post-Gazette
WVU Cancer Institute World's First to Treat Ultra-Rare Leukemia Using Novel Subcutaneous Immunotherapy - Connect-Bridgeport
WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy - My Buckhannon